Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on August 16, 2013, reporting events occurring between August 16 and August 21, 2013. The company is incorporated in Nevada and operates from Norcross, Georgia.
Key Financial Metrics
The filing details a specific capital raising event rather than periodic financial performance metrics.
- Capital Raised: $3,000,000
- Shares Issued: 500,000 shares of common stock
- Transaction Type: Unregistered private placement
- Investor Count: Single investor
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
On August 16, 2013, the company entered into an agreement to sell equity securities. The transaction was completed on August 20, 2013. This represents a material change in the company's capital structure through the issuance of new shares.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the unregistered sale. The transaction was executed pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933. A press release dated August 21, 2013, is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the final closing date of the $3,000,000 private placement (reported as August 20, 2013).
- Confirm the identity of the single investor and any associated lock-up agreements or rights.
- Review the attached press release (Exhibit 99.1) for details on the intended use of proceeds.
- Check subsequent filings for the impact of the 500,000 new shares on total outstanding share count and dilution.